Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 1/22/2020 (updated 3/28/2024)
With opioid deaths on the rise and fentanyl deaths rapidly increasing, a crisis of this magnitude requires innovative responses at multiple intervention points, including post-overdose, as part of a comprehensive strategy to aid in the treatment of and recovery from opioid use disorders. This article explores law enforcement overdose reversal and post-resuscitation and treatment responses in the newly emerging field of pre-arrest diversion.
Posted 11/21/2019 (updated 3/28/2024)
This report was developed as part of an initiative of the U.S. Department of Health and Human Services (HHS) Office on Women’s Health (OWH) to examine prevention, treatment, and recovery issues for women who misuse opioids, have opioid use disorders (OUDs), and/or overdose on opioids.
Posted 11/19/2019 (updated 3/28/2024)
This document is to assist community leaders, local and regional organizers, non-profit groups, law enforcement, public health, and members of the public in understanding and navigating effective strategies to prevent opioid overdose in their communities.
Posted 12/15/2023 (updated 3/28/2024)
The Opioid-Overdose Reduction Continuum of Care Approach is a guide for policymakers for implementing evidence-based strategies that address opioid overdose.
Posted 7/14/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has compiled a Harm Reduction Framework document that will inform the agency's activities, policies, programs, and practices. The framework document includes SAMHSA's six pillars of harm reduction as well as supporting principles and core practice areas.
Posted 6/5/2023 (updated 3/27/2024)
The Government Accountability Office discusses challenges rural communities face related to healthcare access, such as limited healthcare providers, travel distance and transportation issues, insurance coverage, and access to broadband.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.